MEDNAX (NYSE:MD) had its target price raised by analysts at BMO Capital Markets from $46.00 to $58.00 in a report issued on Monday. The firm currently has a “market perform” rating on the stock. BMO Capital Markets’ price objective indicates a potential upside of 7.53% from the stock’s current price.
MD has been the subject of several other reports. KeyCorp set a $51.00 target price on shares of MEDNAX and gave the stock a “buy” rating in a report on Wednesday, November 1st. Jefferies Group reissued a “hold” rating and issued a $44.00 target price on shares of MEDNAX in a report on Friday, November 3rd. Robert W. Baird increased their target price on shares of MEDNAX from $47.00 to $48.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Citigroup reduced their target price on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a report on Friday, November 3rd. Finally, Piper Jaffray Companies started coverage on shares of MEDNAX in a report on Wednesday, December 13th. They issued an “overweight” rating and a $58.00 target price for the company. Two analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $54.92.
Shares of MEDNAX (NYSE MD) opened at $53.94 on Monday. MEDNAX has a 52-week low of $40.56 and a 52-week high of $72.13. The company has a market cap of $5,051.76, a PE ratio of 15.63, a PEG ratio of 1.47 and a beta of 0.31. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.37 and a current ratio of 1.43.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the transaction, the insider now directly owns 35,569 shares in the company, valued at approximately $1,834,649.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Fuller & Thaler Asset Management Inc. bought a new position in MEDNAX in the 3rd quarter worth approximately $103,000. Denali Advisors LLC bought a new position in MEDNAX in the 3rd quarter worth approximately $185,000. Meiji Yasuda Asset Management Co Ltd. boosted its stake in MEDNAX by 45.3% in the 3rd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock worth $226,000 after purchasing an additional 1,630 shares during the period. Delta Capital Management LLC bought a new position in MEDNAX in the 4th quarter worth approximately $227,000. Finally, QS Investors LLC boosted its stake in MEDNAX by 0.3% in the 2nd quarter. QS Investors LLC now owns 3,812 shares of the company’s stock worth $230,000 after purchasing an additional 12 shares during the period. Institutional investors and hedge funds own 95.22% of the company’s stock.
TRADEMARK VIOLATION WARNING: “BMO Capital Markets Boosts MEDNAX (MD) Price Target to $58.00” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/12/bmo-capital-markets-boosts-mednax-md-price-target-to-58-00.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.